KOSPI Pharmaceutical Index Market Cap Rises by KRW 6.7 Trillion in August

[NEWSMP] The combined market capitalization of the KOSPI Pharmaceutical Index constituents increased in August, buoyed by news of Hanmi Pharmaceutical’s technology licensing deal.

According to the Korea Exchange, the combined market capitalization of the 49 constituents of the KOSPI Pharmaceutical Index, excluding preferred shares, stood at KRW 146.9178 trillion as of the August 31 close, up KRW 6.7981 trillion from KRW 140.1197 trillion at the end of July.

During this period, share prices rose for 40 of the 49 constituents, with their market capitalizations increasing accordingly, while eight stocks saw their share prices decline, leading to decreases in market capitalization.

Among them, Hanmi Pharmaceutical, which announced a major technology licensing deal, saw its share price surge 47.7%. Samyang Biopharm also posted a gain of more than 40%, rising 43.6%.

Shinpoong Pharmaceutical jumped 39.0%, gaining nearly 40%, while HanAll Biopharma rose 37.6%, approaching the 40% mark.

In addition, shares of JW Pharmaceutical climbed 20.0%, while Hyundai Pharm also posted a gain of 19.0%, close to the 20% mark.

Yuhan Corporation, SK Bioscience, Jeil Pharmaceutical, Daewoong Pharmaceutical, Myungmoon Pharm, GC Biopharma, Boryung, Dongwha Pharm, Daewoong, and Dong-A ST also gained more than 10%. In total, 16 stocks, nearly one-third of the index’s constituents, posted double-digit gains.

Shares of Myung In Pharm, Ildong Holdings, Chong Kun Dang Bio, Ildong Pharmaceutical, Yuyu Pharma, Daewon Pharmaceutical, Kyongbo Pharmaceutical, Samsung Pharmaceutical, Kukje Pharma, Handok, Samjin Pharmaceutical, and Kwangdong Pharmaceutical also rose by more than 5% during the period.

Bukwang Pharmaceutical, BioNote, Chong Kun Dang Holdings, JW Life Science, Chong Kun Dang Pharmaceutical, Samsung Biologics, Whanin Pharmaceutical, Ilsung IS, IL-Yang Pharmaceutical, Aprogen, Celltrion, and Reyon Pharmaceutical also posted modest gains.

By contrast, Dongsung Bio Pharm fell 19.1% during the same period, while Aprogen Biologics declined 15.1%, both posting double-digit losses. Youngjin Pharm, Orient Bio, Hana Pharm, Samil Pharmaceutical, Korea United Pharm, and PharmGen Science also posted modest declines.

Meanwhile, Hanmi Pharmaceutical’s market capitalization increased by KRW 2.0369 trillion, from KRW 4.2725 trillion to KRW 6.3094 trillion, as its share price surged nearly 50%.

During the same period, Samsung Biologics' market capitalization increased by KRW 1.5278 trillion, followed by increases of KRW 851.6 billion for HanAll Biopharma, KRW 523.6 billion for Celltrion, KRW 356.9 billion for SK Bioscience, and KRW 307.5 billion for Yuhan Corporation.

In addition, the market capitalization of 11 stocks, including GC Biopharma, Shinpoong Pharmaceutical, Daewoong Pharmaceutical, Samyang Biopharm, and JW Pharmaceutical, increased by more than KRW 100 billion.

Conversely, no stock saw its market capitalization decline by more than KRW 100 billion during the same period, and the combined decrease in market capitalization among the eight stocks that posted declines did not exceed KRW 50 billion.

As of the August 31 close, Samsung Biologics remained the largest by market capitalization at KRW 70.2697 trillion, followed by Celltrion at KRW 43.9414 trillion.

Hanmi Pharmaceutical overtook Yuhan Corporation with a market capitalization of KRW 6.3094 trillion, while Yuhan Corporation also returned to above the KRW 6 trillion mark at KRW 6.1616 trillion.

HanAll Biopharma surpassed SK Bioscience as its market capitalization rose above the KRW 3 trillion mark to KRW 3.1188 trillion, while SK Bioscience also moved back above the KRW 3 trillion mark, reaching KRW 3.0127 trillion.

In addition, GC Biopharma and Daewoong Pharmaceutical remained above the KRW 1 trillion mark with market capitalizations of KRW 1.5087 trillion and KRW 1.4715 trillion, respectively, while Daewoong climbed above the KRW 1 trillion mark to KRW 1.0489 trillion.